Avotermin for the improvement of scar appearance: A new pharmaceutical in a new therapeutic area

Expert Opinion on Investigational Drugs

Volumn 18, Issue 8, 2009, Pages 1231-1239

  Occleston, Nick L ^a   Fairlamb, David ^a   Hutchison, John ^a   O'Kane, Sharon ^a   Ferguson, Mark W J ^a  

^a Renovo   (United Kingdom)

Author keywords

Avotermin; Scar free healing; Scar improvement; Scarring; Skin; TGF 3

Indexed keywords

AVOTERMIN; JUVISTA; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; IMMUNOGENICITY; NONHUMAN; REPRODUCTIVE TOXICITY; REVIEW; SCAR; SINGLE DRUG DOSE; TERATOLOGY; WOUND HEALING;

ANIMALS; CICATRIX; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; RECOMBINANT PROTEINS; SKIN; TRANSFORMING GROWTH FACTOR BETA3; WOUND HEALING;

EID: 68049133319     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903130594     Document Type: Review

References (37)

1. McGrouther DA. Facial disfigurement. BMJ 1997;314:991
2. Robert R, Meyer W, Bishop S, et al. Disfiguring burn scars and adolescent self-esteem. Burns 1999;25:581-5
3. Newell R. Psychological difficulties amongst plastic surgery ex-patients following surgery to the face: a survey. Br J Plast Surg 2000;53:386-92
4. Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001;2:135-41
5. Rumsey N, Clarke A, White P. Exploring the psychosocial concerns of outpatients with disfiguring conditions. J Wound Care 2003;12:247-52
6. Lawrence JW, Fauerbach JA, Heinberg L, Doctor M. Visible vs hidden scars and their relation to body esteem. J Burn Care Rehabil 2004;25:25-32
7. Valente SM. Visual disfigurement and depression. Plast Surg Nurs 2004;24(4):140-6
8. Bayat A, McGrouther DA. Clinical management of skin scarring. Skinmed 2005;4:165-73
9. Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002;110:560-71 • Overview of the available clinical literature by an international panel of experts providing evidence-based recommendations on the prevention and treatment of abnormal scarring, with a focus on the management of hypertrophic scars and keloids.
10. Meier K, Nanney LB. Emerging new drugs for scar reduction. Expert Opin Emerg Drugs 2006;11:39-47 •• Comprehensive review of existing treatments, emerging treatments, issues and challenges associated with the development of therapeutics for scar reduction.
11. Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr 2006;18:396-402
12. Berman B, Perez OA, Konda S, et al. A review of the biologic effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol Surg 2007;33:1291-302
13. Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation following burns and trauma: new approaches to treatment. PLoS Med 2007;4:e234
14. Shih R, Waltzman J, Evans GR. Review of over-the-counter topical scar treatment products. Plast Reconstr Surg 2007;119:1091-5
15. O'Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2006;(1):CD003826
16. Reish RG, Eriksson E. Scars: a review of emerging and currently available therapies. Plast Reconstr Surg 2008;122:1068-78. Published online, doi:10.1097/PRS.0b013e318185d38f [doi];00006534-200810000-00010 [pii]
17. Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg 2008;206:719-30. Published online, doi:S1072-7515(07)01929-1 [pii];10.1016/j.jamcollsurg.2007.11.022 [doi]
18. Occleston NL, O'Kane S, Goldspink N, Ferguson MW. New therapeutics for the prevention and reduction of scarring. Drug Discov Today 2008;13:973-81. Published online, doi:S1359-6446(08)00306-1 [pii];10.1016/j. drudis.2008.08.009 [doi] • Review of pharmaceutical approaches in development for scar improvement.
19. Ferguson MWJ, Howarth GF. Marsupial models of scarless fetal wound healing. New York: Elsevier Science, 1991. p. 95-124
20. Whitby DJ, Ferguson MW. The extracellular matrix of lip wounds in fetal, neonatal and adult mice. Development 1991;112:651-68
21. Longaker MT, Whitby DJ, Ferguson MW, et al. Adult skin wounds in the fetal environment heal with scar formation. Ann Surg 1994;219:65-72
22. Armstrong JR, Ferguson MW. Ontogeny of the skin and the transition from scar-free to scarring phenotype during wound healing in the pouch young of a marsupial, Monodelphis domestica. Dev Biol 1995;169:242-60
23. Ferguson MW, Whitby DJ, Shah M, et al. Scar formation: the spectral nature of fetal and adult wound repair. Plast Reconstr Surg 1996;97:854-60
24. Ferguson MW, O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 2004;359:839-50 •• Comprehensive review of regenerative mechanisms of scar-free and scar forming healing, the discovery and translation of therapeutics for scar reduction in adults with a primary focus on TGF-β3.
25. Brockes JP, Kumar A. Appendage regeneration in adult vertebrates and implications for regenerative medicine. Science 2005;310:1919-23 • Review of mechanisms of tissue regeneration in salamanders and the prospect of translation of this understanding in facilitating mammalian regeneration.
26. Longaker MT, Whitby DJ, Adzick NS, et al. Studies in fetal wound healing, VI. Second and early third trimester fetal wounds demonstrate rapid collagen deposition without scar formation. J Pediatr Surg 1990;25:63-8. Published online, doi:S0022346890000203 [pii]
27. Whitby DJ, Ferguson MW. Immunohistochemical localization of growth factors in fetal wound healing. Dev Biol 1991;147:207-15
28. McCallion RL, Ferguson MWJ. Fetal wound healing and the development of antiscarring therapies for adult wound healing. 2nd edition. New York: Plenum Press, 1996. p. 561-600 •• Demonstration of the clinical potential for avotermin to provide an accelerated and permanent improvement in scarring in humans.
29. O'Kane S, Ferguson MWJ. Transforming growth factor betas and wound healing. Int J Biochem Cell Biol 1997;29:63-78
30. Occleston NL, Laverty HG, O'Kane S, Ferguson MWJ. Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFb3): from laboratory discovery to clinical pharmaceutical. J Biomater Sci Polym Ed 2008;19(8):1047-63
31. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700
32. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108(Pt 3):985-1002
33. Coffey RJ, Kost LJ, Lyons RM, et al. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest 1987;80:750-7
34. Dickson K, Philip A, Warshawsky H, et al. Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J Clin Invest 1995;95:2539-54
35. LaMarre J, Hayes MA, Wollenberg GK, et al. An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J Clin Invest 1991;87:39-44
36. Ferguson MW, Duncan J, Bond J, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 2009;373:1264-74. Published online, doi:S0140-6736(09)60322-6 [pii];10.1016/S0140-6736(09)60322-6 [doi]
37. Duncan JA, Bond JS, Mason T, et al. Visual analogue scale scoring and ranking: a suitable and sensitive method for assessing scar quality? Plast Reconstr Surg 2006;118:909-18